OBIO 株価分析 — Orchestra Biomed Holdings Inc. (Healthcare >> Biotechnology)
OBIO に関するよくある質問
OBIOのPER(株価収益率)は?
Orchestra Biomed Holdings Inc.(OBIO)は現在PER 39.50倍で取引されています。
OBIOのROE(自己資本利益率)は?
Orchestra Biomed Holdings Inc.のROEは-107.20%です。
OBIOの配当利回りは?
Orchestra Biomed Holdings Inc.の配当利回りは0.00%です。
OBIOの品質スコア(Quality Score)は?
当社のAIはOBIOの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
OBIOは今が買い時ですか?
当社AIのタイミングスコアは100点中64点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
OBIOはどのセクターに属しますか?
Orchestra Biomed Holdings Inc.はHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
OBIO AI Analysis Summary
Our AI summary for OBIO: Orchestra Biomed Holdings Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 39.50, ROE of -107.20%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 64/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 4.27
Price
0.15
(3.64%)
Day Change
|
|
|---|
OBIO, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.27 |
| PBV / Sector |
4.84 / 44,022.72
|
| Earning Per Share | -0.95 |
| PE / Sector |
39.50 / 19.17
|
| PEG or PE/Growth / Sector |
16.95 / 1.24
|
| Average 1M Daily Value |
0.75 M
GREAT
|
| Average 1W Daily Value |
0.71 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
64% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:00:37 |
| Symbol | OBIO |
| Name | ORCHESTRA BIOMED HOLDINGS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 59.88 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 246.71 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 150 Union Square Drive, New Hope, PA, United States, 18938
Phone: 215 862 5797
Website: https://www.orchestrabiomed.com
Employees: 86
Sector: Healthcare >> Biotechnology
Description: Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google